Abbott Sues India’s Lupin Over Cholesterol Generic
This article was originally published in PharmAsia News
Executive Summary
U.S.-based Abbott Laboratories has filed a suit to stop India's Lupin from selling a generic of Abbott's cholesterol drug Niaspan (niacin). Abbott said in its suit it has seven U.S. patents on the drug, the earliest not set to expire until 2013. The American company, which acquired the drug when it bought Kos Pharmaceuticals in 2006, filed the patent suit in two separate federal courts. (Click here for more
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.